Prostate Cancer

ASCO Updates Recommendations for Lutetium-177-PSMA-617 in mCRPC
The American Society of Clinical Oncology (ASCO) has provided a rapid update on its guideline recommendations for 177Lutetium-PSMA-617 (177Lu-PSMA-617) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). In 2014, ASCO published a guideline on systemic therapy for patients with mCRPC. The guideline was revised in 2022 to include updated guidance on the use of 177Lu-PSMA-617. ...
Advertisement

Latest News

Advertisement

Prostate Cancer Knowledge Hubs

Curated clinical content on prostate cancer types, therapies, and technologies

Localized
Localized

Conference Coverage

Advertisement
Trending

Advertisement